Campbell Newman Asset Management Inc. Sells 18,599 Shares of Corcept Therapeutics Incorporated $CORT

Campbell Newman Asset Management Inc. cut its position in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 52.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,931 shares of the biotechnology company’s stock after selling 18,599 shares during the quarter. Campbell Newman Asset Management Inc.’s holdings in Corcept Therapeutics were worth $589,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the company. Pathstone Holdings LLC raised its stake in shares of Corcept Therapeutics by 0.8% in the third quarter. Pathstone Holdings LLC now owns 18,013 shares of the biotechnology company’s stock valued at $1,497,000 after buying an additional 144 shares during the period. Clearstead Advisors LLC grew its position in shares of Corcept Therapeutics by 163.6% in the third quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 193 shares in the last quarter. Gould Capital LLC grew its position in shares of Corcept Therapeutics by 50.0% in the third quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 200 shares in the last quarter. Smartleaf Asset Management LLC grew its position in shares of Corcept Therapeutics by 14.2% in the third quarter. Smartleaf Asset Management LLC now owns 2,025 shares of the biotechnology company’s stock valued at $170,000 after purchasing an additional 252 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. grew its position in shares of Corcept Therapeutics by 8.3% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,389 shares of the biotechnology company’s stock valued at $282,000 after purchasing an additional 260 shares in the last quarter. 93.61% of the stock is currently owned by institutional investors.

Key Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Neutral Sentiment: ClaimsFiler reminds investors of the April 21, 2026 lead‑plaintiff deadline in a class action covering purchases from Oct. 31, 2024 to Dec. 30, 2025; this is a procedural notice that may consolidate litigation activity. ClaimsFiler Reminder
• Negative Sentiment: Rosen Law Firm and Rosen News releases urge investors with losses >$100K to seek lead‑plaintiff status by Apr. 21, highlighting potential significant investor losses and raising probability of a larger, consolidated claim. Rosen Law Firm Notice
• Negative Sentiment: Bronstein, Gewirtz & Grossman announces a class action against Corcept and certain officers for alleged federal securities law violations over the same class period, signaling multiple plaintiffs firms pursuing similar claims. Bronstein Notice
• Negative Sentiment: Pomerantz LLP and other national firms (Hagens Berman, Schall, Glancy Prongay Wolke & Rotter, Kahn Swick & Foti, Frank R. Cruz) have issued investor alerts encouraging filing for lead‑plaintiff status, amplifying the attention and likelihood of coordinated litigation. Pomerantz Alert
• Negative Sentiment: Earlier filings and press statements cite alleged FDA approval issues and a prior ~50% stock decline as the basis for claims; if successful, litigation could lead to material damages or settlements and increased scrutiny from investors and regulators. KSF Notice

Insider Transactions at Corcept Therapeutics

In other news, Director G Leonard Baker, Jr. acquired 100,000 shares of the business’s stock in a transaction dated Tuesday, March 17th. The stock was purchased at an average cost of $33.14 per share, for a total transaction of $3,314,000.00. Following the acquisition, the director owned 1,146,631 shares of the company’s stock, valued at $37,999,351.34. This trade represents a 9.55% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider William Guyer sold 20,000 shares of the company’s stock in a transaction dated Tuesday, April 7th. The stock was sold at an average price of $40.97, for a total value of $819,400.00. Following the completion of the transaction, the insider owned 2,231 shares of the company’s stock, valued at $91,404.07. The trade was a 89.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 86,198 shares of company stock worth $3,668,569. 20.80% of the stock is currently owned by corporate insiders.

Corcept Therapeutics Price Performance

Corcept Therapeutics stock opened at $43.96 on Friday. Corcept Therapeutics Incorporated has a 52 week low of $28.66 and a 52 week high of $91.00. The business has a 50-day simple moving average of $37.83 and a 200 day simple moving average of $57.35. The company has a quick ratio of 2.85, a current ratio of 2.92 and a debt-to-equity ratio of 0.01. The stock has a market cap of $4.68 billion, a price-to-earnings ratio of 53.61 and a beta of 0.25.

Corcept Therapeutics (NASDAQ:CORT) last posted its earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.13). Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.The business had revenue of $202.13 million for the quarter, compared to analysts’ expectations of $254.94 million. During the same quarter in the previous year, the firm earned $0.26 earnings per share. Corcept Therapeutics’s quarterly revenue was up 11.1% compared to the same quarter last year. On average, research analysts forecast that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CORT has been the subject of several recent research reports. Wolfe Research upgraded Corcept Therapeutics from an “underperform” rating to a “peer perform” rating in a research report on Thursday, March 26th. HC Wainwright reduced their price target on Corcept Therapeutics from $67.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, March 25th. Truist Financial upgraded Corcept Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Weiss Ratings reiterated a “hold (c)” rating on shares of Corcept Therapeutics in a research report on Monday, December 29th. Finally, Canaccord Genuity Group lifted their price target on Corcept Therapeutics from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Corcept Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $77.67.

Corcept Therapeutics Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.